Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial

Inhibikase Therapeutics, Inc.

Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.
Cash and marketable securities $178.8M at Dec 31, 2025, up from $97.5M.
Closed $115M public offering of common stock and pre-funded warrants in Nov 2025.
Initiated global adaptive Phase 3 IMPROVE-PAH study for IKT-001 in PAH; Part A (140 pts, PVR) then Part B (346 pts, 6MWD).
Regulatory submissions in >20 countries; FAST-EU acceptance for accelerated trial approval.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.

Period: year ended December 31, 2025
Net income: $48.3 million
EPS: $0.49 per share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.